Generated: April 28, 2017
|Title:||7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives|
|Abstract:||7-(1-Pyrrolidinyl)-3-quinolone- and -naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives, of the formula ##STR1## in which X.sup.1 is halogen, X.sup.2 is hydrogen, halogen, amino or other radical, R.sup.1 is alkyl, cycloalkyl, optionally substituted phenyl or other radical, R.sup.2 is hydrogen, alkyl or a dioxolylmethyl radical, R.sup.3 is ##STR2## and A is N, CH, C-halogen, or the like, or forms a bridge with R.sup.1, and addition products thereof.|
|Inventor(s):||Petersen; Uwe (Leverkusen, DE), Schenke; Thomas (Bergisch-Gladbach, DE), Krebs; Andreas (Odenthal-Holz, DE), Grohe; Klaus (Odenthal, DE), Schriewer; Michael (Odenthal, DE), Haller; Ingo (Wuppertal, DE), Metzger; Karl G. (Wuppertal, DE), Endermann; Rainer (Wuppertal, DE), Zeiler; Hans-Joachim (Velbert, DE)|
|Assignee:||Bayer Aktiengesellschaft (Leverkusen, DE)|
Patent Claim Types:|
see list of patent claims
|Compound; Composition; Use;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|European Patent Office||0350733||► Subscribe||300111||Netherlands||► Subscribe|
|European Patent Office||0350733||► Subscribe||SPC/GB03/034||United Kingdom||► Subscribe|
|European Patent Office||0350733||► Subscribe||2001C/030||Belgium||► Subscribe|
|European Patent Office||0350733||► Subscribe||11/2000||Austria||► Subscribe|
|European Patent Office||0350733||► Subscribe||C300111||Netherlands||► Subscribe|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.